ID   Ma-Mel-61c
AC   CVCL_S666
DR   cancercelllines; CVCL_S666
DR   Cosmic; 2686448
DR   GEO; GSM2545595
DR   Progenetix; CVCL_S666
DR   Wikidata; Q54903830
RX   PubMed=23348503;
RX   PubMed=28561041;
CC   Sequence variation: Gene deletion; HGNC; 6190; JAK1; Zygosity=Heterozygous (PubMed=28561041).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503).
CC   Omics: SNP array analysis.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C291 ! Ma-Mel-61a
OI   CVCL_C292 ! Ma-Mel-61b
OI   CVCL_S667 ! Ma-Mel-61e
OI   CVCL_S668 ! Ma-Mel-61f
OI   CVCL_S669 ! Ma-Mel-61g
OI   CVCL_S670 ! Ma-Mel-61h
SX   Male
AG   29Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 10-09-24; Version: 12
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=28561041; DOI=10.1038/ncomms15440; PMCID=PMC5460020;
RA   Sucker A., Zhao F., Pieper N., Heeke C., Maltaner R., Stadtler N.,
RA   Real B., Bielefeld N., Howe S., Weide B., Gutzmer R., Utikal J.S.,
RA   Loquai C., Gogas H., Klein-Hitpass L., Zeschnigk M., Westendorf A.M.,
RA   Trilling M., Horn S., Schilling B., Schadendorf D., Griewank K.G.,
RA   Paschen A.;
RT   "Acquired IFNgamma resistance impairs anti-tumor immunity and gives
RT   rise to T-cell-resistant melanoma lesions.";
RL   Nat. Commun. 8:15440.1-15440.15(2017).
//